EYE vs. GKOS, NARI, INSP, IRTC, BLCO, TMDX, SLNO, NVST, PRCT, and LIVN
Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), PROCEPT BioRobotics (PRCT), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.
National Vision vs.
National Vision (NASDAQ:EYE) and Glaukos (NYSE:GKOS) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.
National Vision currently has a consensus price target of $17.75, suggesting a potential downside of 4.83%. Glaukos has a consensus price target of $134.67, suggesting a potential upside of 41.78%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than National Vision.
In the previous week, National Vision had 10 more articles in the media than Glaukos. MarketBeat recorded 20 mentions for National Vision and 10 mentions for Glaukos. Glaukos' average media sentiment score of 1.43 beat National Vision's score of 1.18 indicating that Glaukos is being referred to more favorably in the news media.
99.0% of Glaukos shares are held by institutional investors. 2.7% of National Vision shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
National Vision has a net margin of -0.81% compared to Glaukos' net margin of -39.04%. National Vision's return on equity of 3.52% beat Glaukos' return on equity.
Glaukos received 199 more outperform votes than National Vision when rated by MarketBeat users. Likewise, 65.19% of users gave Glaukos an outperform vote while only 64.50% of users gave National Vision an outperform vote.
National Vision has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
National Vision has higher revenue and earnings than Glaukos. National Vision is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.
Summary
Glaukos beats National Vision on 10 of the 18 factors compared between the two stocks.
Get National Vision News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
National Vision Competitors List
Related Companies and Tools
This page (NASDAQ:EYE) was last updated on 5/22/2025 by MarketBeat.com Staff